

REVIEW

Open Access



# Hand and environmental hygiene: respective roles for MRSA, multi-resistant gram negatives, *Clostridioides difficile*, and *Candida* spp.

John M. Boyce<sup>1\*</sup>

## Abstract

Healthcare-associated infections (HAIs) caused by multidrug-resistant organisms (MDROs) represent a global threat to human health and well-being. Because transmission of MDROs to patients often occurs via transiently contaminated hands of healthcare personnel (HCP), hand hygiene is considered the most important measure for preventing HAIs. Environmental surfaces contaminated with MDROs from colonized or infected patients represent an important source of HCP hand contamination and contribute to transmission of pathogens. Accordingly, facilities are encouraged to adopt and implement recommendations included in the World Health Organization hand hygiene guidelines and those from the Society for Healthcare Epidemiology of America/Infectious Diseases Society of America/Association for Professionals in Infection Control and Epidemiology. Alcohol-based hand rubs are efficacious against MDROs with the exception of *Clostridioides difficile*, for which soap and water handwashing is indicated. Monitoring hand hygiene adherence and providing HCP with feedback are of paramount importance. Environmental hygiene measures to curtail MDROs include disinfecting high-touch surfaces in rooms of patients with *C. difficile* infection daily with a sporicidal agent such as sodium hypochlorite. Some experts recommend also using a sporicidal agent in rooms of patients colonized with *C. difficile*, and for patients with multidrug-resistant Gram-negative bacteria. Sodium hypochlorite, hydrogen peroxide, or peracetic acid solutions are often used for daily and/or terminal disinfection of rooms housing patients with *Candida auris* or other MDROs. Products containing only a quaternary ammonium agent are not as effective as other agents against *C. auris*. Portable medical equipment should be cleaned and disinfected between use on different patients. Detergents are not recommended for cleaning high-touch surfaces in MDRO patient rooms, unless their use is followed by using a disinfectant. Facilities should consider using a disinfectant instead of detergents for terminal cleaning of floors in MDRO patient rooms. Education and training of environmental services employees is essential in assuring effective disinfection practices. Monitoring disinfection practices and providing personnel with performance feedback using fluorescent markers, adenosine triphosphate assays, or less commonly cultures of surfaces, can help reduce MDRO transmission. No-touch disinfection methods such as electrostatic spraying, hydrogen peroxide vapor, or ultraviolet light devices should be considered for terminal disinfection of MDRO patient rooms. Bundles with additional measures are usually necessary to reduce MDRO transmission.

**Keywords** Hand hygiene, Environmental hygiene, Multidrug-resistant organisms, Alcohol-based hand rub, Cleaning, Disinfection

\*Correspondence:

John M. Boyce  
jmboyce69@gmail.com

<sup>1</sup> J.M. Boyce Consulting, LLC, 214 Hudson View Terrace, Hyde Park, NY, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

## Introduction

Infections caused by multidrug-resistant organisms (MDROs) represent a significant public health burden throughout the world, resulting in an estimated 1.27 million deaths attributable directly to MDROs [1]. Deaths attributable to MDROs were frequently caused by methicillin-resistant *Staphylococcus aureus* (MRSA), third-generation cephalosporin-resistant *Escherichia coli*, carbapenem-resistant *Acinetobacter baumannii* (CRAB), fluoroquinolone-resistant *E. coli*, carbapenem-resistant *Klebsiella pneumoniae* (CRKP), and third-generation cephalosporin-resistant *K. pneumoniae* [1]. Equally concerning is the increased prevalence in recent years of multidrug-resistant (MDR) *Pseudomonas aeruginosa*, extended spectrum  $\beta$ -lactamase producing *Enterobacterales*, and MDR *C. auris* [2–11].

Although some progress had been made in reducing infections caused by MRSA, MDR *P. aeruginosa*, and carbapenem-resistant *Acinetobacter* in the years prior to the COVID-19 pandemic [2, 12], data from the United States revealed that MDRO infections among hospitalized patients increased considerably from 2019 to 2020 due to the pandemic [13]. The purpose of this paper is to review the respective roles of hand hygiene and environmental disinfection on prevention of infections caused by MRSA, multidrug-resistant Gram-negative bacteria, *C. difficile*, and *C. auris*.

## Modes of hand transmission

Limiting transmission of MDROs to susceptible patients is the cornerstone of preventing infections due to these pathogens. Transmission of pathogens from one patient to another via contaminated hands of healthcare personnel (HCP) is a common means by which patients acquire nosocomial pathogens, and as a result, hand hygiene is considered the most important measure for preventing healthcare-acquired infections (HAIs) [14–16].

Indirect transmission of pathogens from one patient to another requires that several events must occur [15].

- (1) Patients colonized or infected with healthcare-associated pathogens must have the organisms on their skin or in their secretions or excretions, or shed them onto environmental surfaces in their immediate vicinity.
- (2) Pathogens on contaminated surfaces must survive for some time, often persisting for days to several weeks.
- (3) Pathogens must be transferred from the patient or environmental surfaces to the hands or gloves of HCP and remain viable for at least several minutes.

- (4) HCP must perform hand hygiene using suboptimal technique, use an ineffective antiseptic agent, or fail to perform hand hygiene when indicated.
- (5) Contaminated hands of HCP must come in direct contact with another patient, or with an environmental surface that will subsequently come in contact with another patient.

Patients cared for in hospitals and post-acute care facilities are frequently colonized or infected with MDROs due to previous exposures to antibiotics [2, 9, 17–31]. Frequent colonizers include MRSA, vancomycin-resistant enterococci (VRE), multidrug-resistant Gram-negative bacteria (MDR-GNB); *C. difficile*, and *Candida* spp., with *C. auris* becoming common in recent years.

Affected patients/residents are usually colonized at multiple body sites with MDROs such as MRSA [17, 21, 32–34], MDR-GNB [17], *C. difficile* infection (CDI) [35, 36], and *Candida* spp. [4, 7, 29, 30, 37]. Common sites include the groin, rectum, abdomen, chest, forearms and hands.

Patients colonized or infected with MDROs shed skin squames containing pathogens and contaminate objects in their immediate surroundings that are frequently touched by HCP (so-called high-touch surfaces [HTSs]), the floor in the vicinity of their bed, their toilet, and portable reusable equipment [3, 7, 8, 15, 17, 28, 34, 36, 38–47]. Commonly contaminated sites include bedside rails, bedside tables, intravenous pumps, and supply carts [37, 38, 41, 42, 48–52]. The greater the level of MDRO colonization of a patient's skin and other body sites, the greater the degree of environmental contamination with MDROs such as MDR-*Acinetobacter* and *C. auris* [24, 37, 53]. Patients whose hands are colonized with MDROs may serve as a reservoir for environmental contamination [17, 34].

The level of surface contamination is often greatest in contact precautions (isolation) rooms housing patients with MDROs: some studies reported a frequency of 9.8–90% [34, 36, 38, 41, 43, 54]. Lower contamination rates occur in non-contact precaution patient rooms and other patient care areas [43, 44, 46, 54]. The percentage of contact precautions rooms contaminated with one or more MDROs was 40–71% in several studies [38, 41, 42, 55]. Mobile patient care equipment may also become contaminated with MDROs, including *C. auris* [7, 8, 45, 56, 57]. Asymptomatic *C. difficile* carriers are significantly less likely to have skin colonization and/or shed organisms into their environment [58], but can still be a source of transmission to other patients [59]. Rectal, perianal or stool colonization alone can increase the risk of transmission of pathogens such as *A. baumannii* and MRSA [52, 60, 61]. Patients with diarrhea and concomitant

gastrointestinal colonization or infection with pathogens such as *C. difficile*, MRSA, or VRE are especially likely to contaminate their immediate environment and the gloves of HCPs [38, 58, 62–65].

*Clostridioides difficile* spores and MRSA often cause extensive contamination of dry surfaces [21, 28, 34, 38, 43, 63]. Some studies cite low rates of environmental contamination by MDR-GNB, [66] while others have documented substantial environmental contamination by carbapenem-resistant Enterobacteriaceae (CRE) and MDR-AB [41, 67, 68]. MDR-GNB such as *P. aeruginosa* are frequently recovered from moist surfaces such as sinks, which are increasingly recognized as a source of MDR-GNB colonization and infection [69–72]. *Candida* spp., including *C. auris*, have also been recovered from environmental surfaces in healthcare settings [3, 7, 73, 74].

MDROs including MRSA, MDR-GNB (especially *A. baumannii*), *C. difficile*, and *Candida* spp. (including *C. auris*) can survive on dry surfaces for varying time periods, ranging from several days to weeks or months [73, 75–81]. As a result, contaminated surfaces can be a source of pathogen transmission to patients [28].

Hands and/or gloves of HCP frequently become contaminated during patient care activities [15, 27, 82–84]. This can occur following either contact with the patient's skin or with surfaces near the patient. Direct contact with a patient's colonized skin can transfer pathogens including Gram-negative bacteria, MRSA and *C. difficile* to the hands of HCP [35, 38, 50, 84–89]. Hand contacts with other surfaces also occur frequently, as often as every 4.2 s in some intensive care unit settings, with touching mobile objects or immobile surfaces accounting for a majority of the hand-to-surface contacts [90]. Not surprisingly, contact with contaminated environmental surfaces can also result in contamination of the hands or gloves of HCP [15, 27, 42, 47–49, 51, 83, 91–96]. Wolfensberger et al. [83] found that the average rates of transfer of MDROs following contact with patients or their environment to hands and gloves were 33% and 30%, respectively.

A review of 59 studies by Montoya et al. [84] found that the frequency of hand contamination among HCP varies by pathogen, with following pooled prevalence rates [and ranges] having been reported: MRSA (4.3% [0–39.5%]), vancomycin-resistant enterococci (9.0% [0–55.3%]), *Pseudomonas* spp. (4.6% [0–28.3%]) and *Acinetobacter* spp. (6.2% [0.6–28.6%]), with hand contamination by *C. difficile* varying from 0 to 10.7%.

Others have reported higher rates of *C. difficile* hand contamination among HCP, varying from 14 to 59% [38, 62, 87, 92]. *Candida* spp. not uncommonly contaminates the hands of HCP [97–100]. HCP hand contamination by

*C. auris* has been reported, but may not be as common as with other species [6, 101, 102]. The risk of HCP hand contamination depends on part on the type and duration of patient care provided, the presence of invasive devices, and the extent of environmental contamination [27, 38, 103, 104]. The greater the extent of environmental contamination, the greater the risk of contamination of HCP hands [38]. Caring for patients colonized or infected with MDROs also frequently results in contamination of the gloves of HCP [82, 83, 105–108]. Hands may become contaminated despite wearing gloves, and may occur during glove removal, with a frequency ranging from 2.6 to 29% [65, 87, 105–107, 109].

*Staphylococcus aureus*, Gram-negative bacteria, *C. difficile* and *Candida* spp. can survive on human skin for enough of time to permit possible transmission from contaminated hands. Some pathogens survive on skin for at least several minutes, while others survive for 1 h or longer [77, 110–116]. Transmission from contaminated hands to patients or environmental surfaces may occur if HCP do not perform appropriate hand hygiene when indicated [16], fail to perform hand hygiene, or if contaminated gloves are not removed after contact and are used when caring for a subsequent patient. Evidence of transmission of pathogens from contaminated hands is exemplified by outbreaks due to multidrug-resistant *Staphylococcus epidermidis*, *Citrobacter diversus*, *Pseudomonas aeruginosa*, *Serratia marcescens*, *K. pneumoniae*, and *C. tropicalis* [15, 117–126]. Most of the above-mentioned outbreaks were due to persistent colonization of HCP fingernails or hand dermatitis. Although transient contamination of HCP hands is infinitely more common, documenting individual instances of transmission is much more difficult.

When patients are mobile, modeling studies utilizing silicon nanoparticles with encapsulated DNA provide evidence that pathogens colonizing a patient's skin can be transmitted indirectly to another patient following mutual contact with contaminated surfaces, such as toilet seats [127]. Pathogens can also be transmitted indirectly from one patient to another if contaminated surfaces are not adequately disinfected. Multiple studies have demonstrated that inadequate disinfection of rooms following a patient's discharge puts patients subsequently admitted to the same room at increased risk of acquiring pathogens harbored by the preceding occupant [128].

### Measures to prevent hand transmission of MDROs

Prevention and control of MDROs requires implementing a bundle of measures, with bundles varying in content depending on the target pathogens, as outlined in published guidelines and review articles [8, 129–135]. Strategies to improve hand hygiene are

frequently included in such bundles, since poor hand hygiene compliance often contributes to transmission of MDROs [11, 135–137].

The 2009 WHO hand hygiene guidelines and those recently published by the Society for Healthcare Epidemiology of America (SHEA)/Infectious Diseases Society of America (IDSA)/Association for Professionals in Infection Control and Epidemiology (APIC) both outline policies and practices designed to reduce transmission of healthcare-associated pathogens of all types, including MDROs [16, 138]. Accordingly, healthcare facilities are encouraged to adopt and implement recommendations included in the WHO or SHEA/IDSA/APIC hand hygiene guidelines [16, 138]. The combination of implementing the WHO multimodal strategy, promoting the use of alcohol-based hand rub (ABHR) as the preferred method of hand hygiene, and promoting the WHO 5 Moments for Hand Hygiene indications for hand hygiene have been shown to yield higher compliance rates [139, 140]. And implementing multimodal hand hygiene strategies has been shown to contribute to the reduction of HAIs due to MDROs [141–145].

ABHR is preferred method for hand hygiene against almost all pathogens, including MDROs such as MRSA, MDR-GNB, and *C. auris* [16, 138, 146, 147]. For preventing infections caused by pathogens with reduced susceptibility to ABHR (e.g., *C. difficile* and norovirus), there remains some debate regarding the role of ABHR due to mixed data regarding ABHR efficacy against norovirus based on product formulation and test methodology [148], and because the relative difference in the effectiveness between approved ABHRs and soap and water handwashing on *C. difficile* or norovirus is based solely on laboratory data. Routine use of gloves followed by hand hygiene after glove removal are recommended when caring for patients with *C. difficile* infection [138]. During outbreaks of *C. difficile* or norovirus infections, washing with soap and water is preferred when caring for patients with known or suspected infections [16, 138, 149]. However, ABHR should continue to be readily available when caring for patients with *C. difficile* or norovirus infections during outbreaks [138], and can be useful when used as an adjunct to soap and water handwashing during outbreaks [148, 150]. A few outbreaks of norovirus in hospitals have been controlled by using primarily ABHR with 80–95% ethanol for hand hygiene in conjunction with other measures [151, 152]. A large number of studies provide a solid evidence base showing that long-term use of ABHR is associated with reductions in HAIs [142, 153–156]. Despite its poor activity against *C. difficile* spores, prolonged use of ABHR has not been associated with an increase *C. difficile* infections [154, 157–160].

Based on in vitro data, it may be prudent to avoid hand antiseptics containing 1% chloroxylenol or chlorhexidine (without alcohol) when caring for patients with *C. auris* [146]. Although there is some concern about whether ABHR gel and foam products are sufficiently efficacious [161–165], several studies have concluded that well-formulated ABHR gel and foam products that meet efficacy standards are acceptable for use in healthcare settings [166–169]. A recent literature review failed to identify evidence demonstrating that one format (rinse, gel, or foam) is significantly more effective in preventing transmission of healthcare-associated pathogens or HAIs [170]. The updated SHEA/IDSA/APIC guidance states that liquid, gel and foam ABHRs with at least 60% alcohol are acceptable for use [138]. Facilities should identify and correct deficiencies in hand hygiene infrastructure, such as lack of adequate numbers of readily accessible ABHR dispensers [171, 172]. Increasing the availability of ABHR dispensers and increasing ABHR consumption have been associated with reduction of MDROs [8, 173, 174].

Facilities should also devote greater attention to hand hygiene technique [175]. Errors in hand hygiene technique include applying an inadequate (i.e., low) volume of ABHR on hands, rubbing hands together for too short a time, failure to cover all surfaces adequately, failure to perform hand hygiene after glove removal, and applying ABHR to gloves [11, 175]. Some facilities may choose to promulgate a simplified 3-step procedure (versus the WHO six-step method) for performing hand hygiene using an ABHR as an approach to improving technique and increasing hand hygiene compliance [176]. Additional research is needed to identify the optimum method for applying ABHR on hands [177].

Monitoring HCP performance combined with timely feedback is an essential element of multimodal programs to improve hand hygiene, and can identify trends in compliance rates and areas of suboptimal compliance [16, 138, 142]. Direct observation of HCP by validated observers continues to be the gold standard method, although there is some evidence that automated hand hygiene monitoring systems may be a useful adjunctive strategy [138, 175, 177]. Practical methods for specifically monitoring hand hygiene technique during routine patient care activities are needed [175].

### **Environmental hygiene strategies for prevention of MDRO infections**

The important role of the environment in transmission of HAIs and the need for cleaning and disinfection of environmental surfaces are well-established [72, 178–182]. There is substantial evidence that cleaning and disinfecting environmental surfaces (often accompanied by additional interventions) can reduce patient colonization



and/or HAIs in general, and importantly, infections caused by MDROs [11, 183–186]. Despite the availability of guidance on environmental hygiene programs, considerable variability in implementation exists between different facilities [187, 188]. General elements of a multimodal program, as outlined in several articles, are listed below [182, 184, 189, 190].

#### **Policies/procedures**

Daily application of a disinfectant to HTSs in contact precautions/isolation rooms of patients with MDRO infections is recommended in acute care settings [131, 132, 147, 182, 183, 191, 192]. Because surfaces are frequently contaminated in rooms of patients colonized with MDROs and in rooms without known MDRO patients [54, 193], some experts recommend daily disinfection of HTSs in all patient rooms [54, 182, 183, 190, 192, 194]. Daily use of disinfectants has been shown to reduce MDRO contamination of HCP hands [91], has contributed to reducing MDRO infections in several studies and may reduce MDRO prevalence in long-term care facilities [183, 195]. Policies should state if disinfection of HTSs in MDRO patient rooms should be performed more than once/day [196], a practice adopted in some hospitals [183, 197–199].

Instructions for daily and terminal cleaning and disinfection should include recommendations regarding the number of cloths or wipes to be used per room and when to change mop heads [182]. Reusable buckets used to contain liquid disinfectants should be cared for following manufacturer recommendations to avoid contamination with Gram-negative bacteria [200–202]. Portable equipment such as digital thermometers, temperature probes, ultrasound probes and wheelchairs should be disinfected between use on different patients [7, 45, 183].

Lack of clarity among HCP regarding who is responsible for cleaning and disinfection of HTSs and portable equipment is a relatively common problem. It has been identified as a potential cause of suboptimal environmental hygiene [147, 179]. Accordingly, engaging EVS staff and nursing personnel in formulating detailed policies regarding who is responsible for cleaning various surfaces and products to be used can help rectify misconceptions among personnel [183, 184, 203, 204].

Terminal cleaning and disinfection of rooms vacated by patients with MDROs is recommended to reduce the risk of MDRO infection among patients subsequently admitted to the rooms [128, 131, 182, 183, 191]. Facility policies should address whether “no-touch” disinfection devices (e.g., ultraviolet (UV) light and automated hydrogen peroxide systems) are to be used, an issue of ongoing debate [192, 205, 206]. Administrators need to provide adequate financial resources, sufficient EVS staff, and

appropriate personal protective equipment, and foster a culture that recognizes the essential services provided by EVS personnel. Providing EVS staff with incentives, opportunities for certification, higher pay may improve morale and personnel retention [207, 208].

#### **Cleaning & disinfection products and procedures**

Physical wiping surfaces with a neutral detergent can remove some microorganisms, including *C. difficile* spores [209]. However, detergents are not only less effective than disinfectants in reducing MDROs [210, 211], but can transfer MDROs (including *C. difficile*) from one surface to another [212].

Detergents have commonly been used for cleaning floors, in part because floors have not been considered potential sources of transmission [182, 187]. However, there is continuing debate about whether floors should be cleaned with a detergent or a disinfectant [192, 213]. Evidence in favor of using disinfectants instead of detergents on floors include the following: use of detergents may actually increase colony counts on floors [214, 215]; floors are frequently contaminated with MDROs and can be a potential source of transmission to patients [38, 41, 46, 213, 216], and that using a disinfectant with two or more disposable mop heads per room reduced MRSA, *C. difficile* and *Candida* spp. on floors [45]. As a result, facilities may want to consider using a disinfectant for terminal cleaning of floors in patient rooms [45, 192].

Disinfectants available for use in healthcare settings include products containing alcohol, chlorine-releasing agents (e.g., sodium hypochlorite “bleach”, sodium dichloroisocyanurate), quaternary ammonium compounds alone or combined with alcohol, improved hydrogen peroxide, phenolics, peracetic acid/hydrogen peroxide, dodecylbenzenesulfonic acid, and glucoprotamin [101, 217, 218]. Factors to be considered when selecting disinfectants for use in healthcare facilities have been summarized by Rutala et al. [182]. In-use concentrations of common disinfectants are effective against most healthcare-associated pathogens, with a few notable exceptions [182, 192, 219]. Sporocidal agents are recommended for disinfection of *C. difficile* infection patient rooms [191, 192, 220]. Facility policies should also stipulate if sporocidal agents are also used for daily and/or terminal cleaning of rooms of patients colonized with *C. difficile*, and patients colonized or infected with MDR-GNB or *C. auris* [3]. Some disinfectants with quaternary ammonium compounds as the only active agent are not as effective as other disinfectants against *C. auris* [146, 221], suggesting that products with demonstrated high potency against *C. auris* may be preferable for disinfection of rooms housing patients with *C. auris*. Sodium hypochlorite, hydrogen peroxide, and peracetic acid solutions are commonly

used for decontaminating surfaces contaminated with *C. auris*. In the United States, the Environmental Protection Agency has posted a list of disinfectants (List P) that are appropriate for use against *C. auris* [222]. Exposing *C. auris* to 1000 ppm sodium hypochlorite yielded suboptimal reduction (e.g., 1.3–1.6 log<sub>10</sub>) in several studies, suggesting that higher concentrations should be considered [146, 223].

Pre-impregnated disinfectant wipes have been shown to be effective in reducing total colony counts and MDRO bioburden on surfaces [218, 224–227]. A prospective cluster-controlled crossover trial found that a pre-impregnated hydrogen peroxide-based wipe was significantly better than a quaternary ammonium-based disinfectant at reducing total colony counts on surfaces, and reduced colonization and infection by MDRO pathogens to a greater extent, although the difference between disinfectants did not reach statistical significance [228].

#### Education and training

Education and training of HCP regarding environmental cleaning and disinfection of HTSs, common areas, mobile equipment and reusable equipment are essential elements of multimodal strategies to reduce transmission of healthcare-associated pathogens, including MDROs [130, 147, 190, 229]. EVS staff should receive specific education and training regarding the types of disinfectant in use, methods of application, frequency and sequence of disinfection, list of HTSs, and the importance of following manufacturers' instructions regarding contact times and dilutions, if warranted [185, 190, 195].

One hospital implemented standardized education of EVS staff, validating the knowledge and cleaning competency of new EVS personnel, annual assessment of room-cleaning skills of all EVS personnel and other quality improvement measures, resulting in a significant increase in surface cleaning performance and a sustained reduction of *C. difficile* infection rates over a period of 10 years [230]. Hospital staff involved in use of "no-touch" devices must be adequately trained on how to operate the devices, and ideally receive periodic competency evaluations [231].

#### Monitoring cleaning and disinfection and feedback

Monitoring the effectiveness of cleaning/disinfection procedures and providing EVS and nursing personnel with feedback are essential for preventing infections caused by MDROs and other pathogens [130, 135, 147, 185, 232]. Methods for monitoring the effectiveness of cleaning and disinfection practices include visual assessments of cleanliness, the use of overt or covert direct observation of EVS staff, fluorescent markers, adenosine triphosphate (ATP) assays, and culture methods [181,

233, 234]. The advantages and limitations of the various methods are summarized in the following Table 1.

When using either fluorescent markers or ATP assays, involving infection prevention personnel in assessment of disinfection practices is advisable, since having EVS personnel monitor performance may yield exaggerated compliance rates [230, 233, 245].

#### No-touch technologies

The rationale for considering the use of supplemental no-touch methods include that fact that up to 55% of surfaces in rooms vacated by patients with MRDOs may still be contaminated following terminal disinfection, and that such residual contamination puts subsequent patients at increased risk of acquiring an MDRO [28, 128]. Recently, electrostatic spray devices used to deliver liquid disinfectants to an area have been shown to reduce healthcare-associated pathogens on fixed surfaces and mobile equipment [206]. Automated decontamination systems include devices that emit hydrogen peroxide vapor (HPV), aerosols of hydrogen peroxide (aHP) or peracetic acid, continuous ultraviolet light (UV-C), or pulsed broad-spectrum UV light [246]. All the above types of devices have been shown to reduce the bioburden of pathogens on surfaces. However, they vary in terms of their ability to reduce pathogens on all surfaces in hospital rooms and pathogen-specific log<sub>10</sub> reductions achieved [247]. Although several reviews have concluded that these devices can reduce transmission of healthcare-associated pathogens and/or reduce HAIs, controversy still exists regarding their effectiveness (and cost-effectiveness) and the practicality of their use [147, 205, 206, 246–248].

Of the methodologies mentioned above, HPV produces the greatest log<sub>10</sub> reductions of pathogens and yields the most homogeneous levels of disinfection [247]. HPV has been shown to reduce *C. difficile* infection and VRE acquisition, and appears to have contributed to control of outbreaks due to MRSA, CRE, MDR *Enterobacter cloacae* and *C. auris* [3, 249–251]. A prospective controlled trial found that terminal disinfection of patient rooms reduced patient acquisition of MDROs by 64% [247, 252]. Systems using aHP have been shown to reduce the bioburden of MDR-GNB, MRSA, VRE, *C. difficile* and *C. auris* on environmental surfaces, and when used in conjunction with other measures, resulted in a significant reduction in MRSA infections [247]. Currently, no randomized controlled trials have evaluated the efficacy of HPV or aHP to reduce HAIs.

Continuous or pulsed xenon UV light devices reduced hospital-associated *C. difficile* infection (HACDI) and HAIs due to MRSA, VRE and MDR Gram-negatives in most before-after studies [247, 253]. In a

**Table 1** Advantages and limitations of strategies for monitoring environmental hygiene

Method	Advantages	Limitations
Visual assessments [181, 233, 234]	Possible in all facilities; does not require special equipment; requires less time than other methods; direct observation of and feedback to EVS personnel are possible	Cannot detect residual surface contamination
Direct observation of EVS personnel [229, 235–237]	Can identify suboptimal technique; has contributed to reduction of MDRO transmission	Time consuming; not feasible in some circumstances
Fluorescent markers [46, 179, 181, 190, 230, 233–235, 238, 239]	Multiple studies support its use. Has been shown to improve cleaning compliance rates, reduce surface contamination, nosocomial transmission, and HAIs caused by MDROs. Can provide useful feedback to EVS staff	Complete marker removal does not assure elimination of MDROs from surface; EVS staff occasionally use black light to identify marked surfaces and prioritize those surfaces. Somewhat time-consuming, unless a representative sample of surfaces is selected
Adenosine triphosphate (ATP) assays [179, 181, 233, 234, 236, 240–243]	Can provide immediate feedback to EVS staff and identify variations in cleaning practices. Associated with improved cleaning practices during CRE and CRAB outbreaks; may be useful in monitoring disinfection of CDI patient rooms. Associated with greater reduction of MDRO colonization/infection than fluorescent markers in a cluster-randomized trial	Detects both microorganisms and other organic material; poor correlation between ATP readings and level of microbial contamination; results may vary depending on microbe present. Some disinfectants may cause falsely low assay results. Relatively expensive
Culturing surfaces [8, 28, 46, 54, 67, 181, 229, 233, 241, 244]	Can identify pathogens, including MDROs, on surfaces before and after routine disinfection. Swabs, sponges, contact plates and dip slides can be used to sample surfaces	Requires additional laboratory capabilities; results not available for 24–72 h; relatively expensive; requires the use of a neutralizer if surfaces have been disinfected with a product with residual activity

ATP—adenosine triphosphate; CDI—*C. difficile* infection; CRE—carbapenem-resistant Enterobacteriaceae; CRAB—carbapenem-resistant *Acinetobacter baumannii*; EVS—environmental services personnel; HAIs—healthcare-associated infections; MDRO—multidrug-resistant organisms

multicenter cross-over cluster-randomized controlled trial that compared adding UV-C disinfection to standard disinfection methods, terminal room disinfection using UV-C reduced the incidence of hospital-wide *C. difficile* and VRE, but not *Acinetobacter* spp. or MRSA [254]. In contrast, in a single-center crossover cluster-randomized controlled trial performed in a hospital's four cancer and one solid organ transplant units, daily and terminal room UV-C disinfection did not significantly reduce *C. difficile* or VRE infection rates [248].

Limitations of no-touch technologies include their acquisition costs, cycle time impact on room turnaround times, ease of use, personnel time required to deploy them, the inability to use them in occupied patient rooms, and limited evidence of their ability to reduce HAIs. Accordingly, facilities need to consider the level of their standard cleaning/disinfection proficiency, costs and operational issues of using no-touch systems, and level of MDRO transmission in making decisions regarding their use [192, 206].

Enhanced environmental hygiene strategies include sporicidal disinfectants for MDR-GNB or *C. auris*, increased disinfection frequency (e.g., 2–3 times/day), adding EVS staff, use of specific check lists, removal of implicated contaminated equipment, certification of terminal room disinfection by infection control personnel, which may be combined with antimicrobial stewardship [7, 135, 199, 240, 255–257].

Additional strategies frequently combined with measures to improve hand hygiene and environmental hygiene include contact precautions for patients infected (and in some instances colonized) with MDROs, placing affected patients in isolation or cohorting them, and bathing them with chlorhexidine soap [7, 137, 194, 240, 255]. Surveillance cultures are used to identify patients with unrecognized colonization with certain MDROs such as MDR-GNRs and *C. auris* [7, 101, 137, 255].

In conclusion, implementing bundles that have improved hand hygiene and environmental hygiene has been successful in reducing transmission of MDROs and related HAIs [7, 135, 194, 199, 240, 256].

#### Acknowledgements

Not applicable.

#### Author informations

The author was lead co-author of the CDC Guideline for Hand Hygiene in Health-care Settings, and a contributor to the WHO Guidelines on Hand Hygiene in Health Care, and has published numerous articles dealing with hand hygiene, environmental disinfection, and methods for monitoring cleaning/disinfection of surfaces in hospitals.

#### Author contributions

JMB conducted searches of the PubMed and Google Scholar databases for relevant articles, and reviewed all articles cited in the bibliography, which included many which were accumulated over a period of several decades

while serving as an infectious diseases specialist and hospital epidemiologist. He prepared all versions, including the final version, of the manuscript.

#### Funding

Not applicable. No funding was provided.

#### Availability of data and materials

No datasets were generated or analysed during the current study.

#### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

JMB is a consultant to, has received travel support from, and has spoken at conferences supported by GOJO Industries, and is a consultant to Diversey, a Solenis company.

Received: 27 June 2024 Accepted: 4 September 2024

Published online: 27 September 2024

#### References

1. Antimicrobial RC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399:629–55.
2. Rodriguez-Villodres A, Martin-Gandul C, Penalva G, Guisado-Gil AB, Crespo-Rivas JC, Pachon-Ibanez ME, et al. Prevalence and risk factors for multidrug-resistant organisms colonization in long-term care facilities around the world: a review. *Antibiotics (Basel)*. 2021;10:680.
3. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging *Candida auris* in a European hospital. *Antimicrob Resist Infect Control*. 2016;5:35.
4. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of *Candida auris*, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. *MMWR Morb Mortal Wkly Rep*. 2016;65:1234–7.
5. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant *Candida auris* on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. *Clin Infect Dis*. 2017;64:134–40.
6. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al. *Candida auris*: a review of the literature. *Clin Microbiol Rev*. 2018;31:e00029–e117.
7. Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP, et al. A *Candida auris* outbreak and its control in an intensive care setting. *N Engl J Med*. 2018;379:1322–31.
8. Pacilli M, Kerins JL, Clegg WJ, Walblay KA, Adil H, Kemble SK, et al. Regional emergence of *Candida auris* in Chicago and lessons learned from intensive follow-up at 1 ventilator-capable skilled nursing facility. *Clin Infect Dis*. 2020;71:e718–25.
9. Rossow J, Ostrowsky B, Adams E, Greenko J, McDonald R, Vallabhaneni S, et al. Factors associated with *Candida auris* colonization and transmission in skilled nursing facilities with ventilator units, New York, 2016–2018. *Clin Infect Dis*. 2021;72:e753–60.
10. Kohlenberg A, Monnet DL, Plachouras D. *Candida auris* survey collaborative group. Increasing number of cases and outbreaks caused by *Candida auris* in the EU, EEA, to 2021. *Euro Surveill*. 2020;2022(27):2200846.
11. Thoma R, Seneghini M, Seiffert SN, Vuichard Gysin D, Scanferla G, Haller S, et al. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and *Candida auris* during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant *Acinetobacter baumannii* outbreak and a systematic review of the literature. *Antimicrob Resist Infect Control*. 2022;11:12.



12. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, et al. Multidrug-Resistant Bacterial Infections in US Hospitalized Patients, 2012–2017. *N Engl J Med.* 2020;382:1309–19.
13. Centers for Disease Control and Prevention. COVID-19: U.S. impact on antimicrobial resistance, special report 2022. <https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf>.
14. Boyce JM, Pittet D. Healthcare Infection Control Practices Advisory C, the HSAIHHTF. Guideline for hand hygiene in health-care settings. *Morb Mortal Week Rep.* 2002;51(RR-16):1–45.
15. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, et al. Evidence-based model for hand transmission during patient care and the role of improved practices. *Lancet Infect Dis.* 2006;6:641–52.
16. World Health O. WHO guidelines for hand hygiene in health care. Geneva: World Health Organization; 2009. [https://iris.who.int/bitstream/handle/10665/44102/9789241597906\\_eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/44102/9789241597906_eng.pdf?sequence=1).
17. Mody L, Washer LL, Kaye KS, Gibson K, Saint S, Reyes K, et al. Multidrug-resistant organisms in hospitals: what is on patient hands and in their rooms? *Clin Infect Dis.* 2019;69:1837–44.
18. Mody L, Foxman B, Bradley S, McNamara S, Lansing B, Gibson K, et al. Longitudinal assessment of multidrug-resistant organisms in newly admitted nursing facility patients: implications for an evolving population. *Clin Infect Dis.* 2018;67:837–44.
19. McKinnell JA, Singh RD, Miller LG, Kleinman K, Gussin G, He J, et al. The SHIELD orange county project: multidrug-resistant organism prevalence in 21 nursing homes and long-term acute care facilities in Southern California. *Clin Infect Dis.* 2019;69:1566–73.
20. Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. *Pediatr Crit Care Med.* 2008;9:91–5.
21. Chang S, Sethi AK, Stiefel U, Cadnum JL, Donskey CJ. Occurrence of skin and environmental contamination with methicillin-resistant *Staphylococcus aureus* before results of polymerase chain reaction at hospital admission become available. *Infect Control Hosp Epidemiol.* 2010;31:607–12.
22. Ludden C, Cormican M, Vellinga A, Johnson JR, Austin B, Morris D. Colonisation with ESBL-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant enterococci, and methicillin-resistant *Staphylococcus aureus* in a long-term care facility over one year. *BMC Infect Dis.* 2015;15:168.
23. Donskey CJ, Kundrapu S, Deshpande A. Colonization versus carriage of *Clostridium difficile*. *Infect Dis Clin North Am.* 2015;29:13–28.
24. Nutman A, Lerner A, Schwartz D, Carmeli Y. Evaluation of carriage and environmental contamination by carbapenem-resistant *Acinetobacter baumannii*. *Clin Microbiol Infect.* 2016;22:949.e5–949.e7.
25. Thurlow CJ, Prabaker K, Lin MY, Lolans K, Weinstein RA, Hayden MK, et al. Anatomic sites of patient colonization and environmental contamination with *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae at long-term acute care hospitals. *Infect Control Hosp Epidemiol.* 2013;34:56–61.
26. Crobach MJT, Vernon JJ, Loo VG, Kong LY, Pechine S, Wilcox MH, et al. Understanding *Clostridium difficile* colonization. *Clin Microbiol Rev.* 2018;31:e00021–e117.
27. Mills JP, Zhu Z, Mantey J, Hatt S, Patel P, Kaye KS, et al. The devil is in the details: factors influencing hand hygiene adherence and contamination with antibiotic-resistant organisms among healthcare providers in nursing facilities. *Infect Control Hosp Epidemiol.* 2019;40:1394–9.
28. Chen LF, Knelson LP, Gergen MF, Better OM, Nicholson BP, Woods CW, et al. A prospective study of transmission of Multidrug-Resistant Organisms (MDROs) between environmental sites and hospitalized patients—the TransFER study. *Infect Control Hosp Epidemiol.* 2019;40:47–52.
29. Proctor DM, Dangana T, Sexton DJ, Fukuda C, Yelin RD, Stanley M, et al. Integrated genomic, epidemiologic investigation of *Candida auris* skin colonization in a skilled nursing facility. *Nat Med.* 2021;27:1401–9.
30. Piatti G, Sartini M, Cusato C, Schito AM. Colonization by *Candida auris* in critically ill patients: role of cutaneous and rectal localization during an outbreak. *J Hosp Infect.* 2022;120:85–9.
31. van Dulm E, Tholen ATR, Pettersson A, van Rooijen MS, Willemsen I, Molenaar P, et al. High prevalence of multidrug resistant Enterobacteriaceae among residents of long term care facilities in Amsterdam, the Netherlands. *PLoS ONE.* 2019;14:e0222200.
32. Rohr U, Wilhelm M, Muhr G, Gatermann S. Qualitative and (semi) quantitative characterization of nasal and skin methicillin-resistant *Staphylococcus aureus* carriage of hospitalized patients. *Int J Hyg Environ Health.* 2004;207:51–5.
33. Sanford MD, Widmer AF, Bale MJ, Jones RN, Wenzel RP. Efficient detection and long-term persistence of the carriage of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 1994;19:1123–8.
34. Wolfensberger A, Mang N, Gibson KE, Gontjes K, Cassone M, Brugger SD, et al. Understanding short-term transmission dynamics of methicillin-resistant *Staphylococcus aureus* in the patient room. *Infect Control Hosp Epidemiol.* 2022;43:1147–54.
35. Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. Clostridium difficile skin contamination in patients with *C. difficile*-associated disease. *Clin Infect Dis.* 2008;46:447–50.
36. Sethi AK, Al-Nassir WN, Nernandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of *Clostridium difficile* during and after treatment of *C. difficile* infection. *Infect Control Hosp Epidemiol.* 2010;31:21–7.
37. Sexton DJ, Bentz ML, Welsh RM, Derado G, Furin W, Rose LJ, et al. Positive correlation between *Candida auris* Skin-colonization burden and environmental contamination at a ventilator-capable skilled nursing facility in Chicago. *Clin Infect Dis.* 2021;73:1142–8.
38. Samore MH, Venkataraman L, Degirolami PC, Levin E, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial *Clostridium difficile* diarrhea. *Am J Med.* 1996;100:32–40.
39. Rohr U, Kaminski A, Wilhelm M, Jurzik L, Gatermann S, Muhr G. Colonization of patients and contamination of the patients' environment by MRSA under conditions of single-room isolation. *Int J Hyg Environ Health.* 2009;212:209–15.
40. Chang HL, Tang CH, Hsu YM, Wan L, Chang YF, Lin CT, et al. Nosocomial outbreak of infection with multidrug-resistant *Acinetobacter baumannii* in a medical center in Taiwan. *Infect Control Hosp Epidemiol.* 2009;30:34–8.
41. Thom KA, Johnson JK, Lee MS, Harris AD. Environmental contamination because of multidrug-resistant *Acinetobacter baumannii* surrounding colonized or infected patients. *Am J Infect Control.* 2011;39:711–5.
42. Morgan DJ, Rogawski E, Thom KA, Johnson JK, Perencevich EN, Shardell M, et al. Transfer of multidrug-resistant bacteria to healthcare workers' gloves and gowns after patient contact increases with environmental contamination. *Crit Care Med.* 2012;40:1045–51.
43. Ali S, Muzslay M, Wilson P. A novel quantitative sampling technique for detection and monitoring of *Clostridium difficile* contamination in the clinical environment. *J Clin Microbiol.* 2015;53:2570–4.
44. Cheng VCC, Wong SC, Chen JHK, So SYC, Wong SCY, Ho PL, et al. Control of multidrug-resistant *Acinetobacter baumannii* in Hong Kong: role of environmental surveillance in communal areas after a hospital outbreak. *Am J Infect Control.* 2018;46:60–6.
45. Donskey CJ. Beyond high-touch surfaces: portable equipment and floors as potential sources of transmission of health care-associated pathogens. *Am J Infect Control.* 2019;47S:A90–5.
46. Cadnum JL, Pearlmutter BS, Jencson AL, Haydar H, Hecker MT, Ray AJ, et al. Microbial bioburden of inpatient and outpatient areas beyond patient hospital rooms. *Infect Control Hosp Epidemiol.* 2022;43:1017–21.
47. Boyce JM, Potter-Bynoe G, Chenevert C, King T. Environmental contamination due to methicillin-resistant *Staphylococcus aureus*: possible infection control implications. *Infect Control Hosp Epidemiol.* 1997;18:622–7.
48. Bhalla A, Pultz NJ, Gries DM, Ray AJ, Eckstein EC, Aron DC, et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. *Infect Control Hosp Epidemiol.* 2004;25:164–7.
49. Boyce JM. Environmental contamination makes an important contribution to hospital infection. *J Hosp Infect.* 2007;65(Suppl 2):50–4.
50. Casewell M, Phillips I. Hands as route of transmission for *Klebsiella* species. *Br Med J.* 1977;2:1315–7.
51. Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with *Clostridium difficile* infection and with environmental surfaces in their rooms. *Am J Infect Control.* 2012;40:556–8.
52. Rosa R, Depascale D, Cleary T, Fajardo-Aquino Y, Kett DH, Munoz-Price LS. Differential environmental contamination with *Acinetobacter baumannii* based on the anatomic source of colonization. *Am J Infect Control.* 2014;42:755–7.

53. Sansom SE, Gussin GM, Schoeny M, Singh RD, Adil H, Bell P, et al. Rapid environmental contamination with *Candida auris* and multidrug-resistant bacterial pathogens near colonized patients. *Clin Infect Dis*. 2024;78:1276–84.
54. Tanner WD, Leecaster MK, Zhang Y, Stratford KM, Mayer J, Visnovsky LD, et al. Environmental contamination of contact precaution and non-contact precaution patient rooms in six acute care facilities. *Clin Infect Dis*. 2021;72(Supplement1):S8–16.
55. Shams AM, Rose LJ, Edwards JR, Cali S, Harris AD, Jacob JT, et al. Assessment of the overall and multidrug-resistant organism bioburden on environmental surfaces in healthcare facilities. *Infect Control Hosp Epidemiol*. 2016;37:1426–32.
56. van den Berg RW, Claahsen HL, Niessen M, Muytjens HL, Liem K, Voss A. Enterobacter cloacae outbreak in the NICU related to disinfected thermometers. *J Hosp Infect*. 2000;45:29–34.
57. Kanamori H, Rutala WA, Weber DJ. The role of patient care items as a fomite in healthcare-associated outbreaks and infection prevention. *Clin Infect Dis*. 2017;65:1412–9.
58. Guerrero DM, Becker JC, Eckstein EC, Kundrapu S, Deshpande A, Sethi AK, et al. Asymptomatic carriage of toxigenic *Clostridium difficile* by hospitalized patients. *J Hosp Infect*. 2013;85:155–8.
59. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in *Clostridium difficile* transmission. *Clin Infect Dis*. 2013;57:1094–102.
60. Kim JJ, Johnson JK, Stucke EM, Sorkin JD, Zhao L, Lydecker A, et al. Burden of perianal *Staphylococcus aureus* colonization in nursing home residents increases transmission to healthcare worker gowns and gloves. *Infect Control Hosp Epidemiol*. 2020;41:1396–401.
61. Bhalla A, Aron DC, Donskey CJ. *Staphylococcus aureus* intestinal colonization is associated with increased frequency of *S. aureus* on skin of hospitalized patients. *BMC Infect Dis*. 2007;7:105.
62. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med*. 1989;320:204–10.
63. Boyce JM, Havill NL, Otter JA, Adams NMT. Widespread environmental contamination associated with patients with diarrhea and methicillin-resistant *Staphylococcus aureus* colonization of the gastrointestinal tract. *Infect Control Hosp Epidemiol*. 2007;28:1142–7.
64. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multidrug-resistant *Enterococcus faecium* with transferable vanB class vancomycin resistance. *J Clin Microbiol*. 1994;32:1148–53.
65. Tenorio AR, Badri SM, Sahgal NB, Hota B, Matushek M, Hayden MK, et al. Effectiveness of gloves in preventing personnel handcarriage of vancomycin-resistant enterococcus (VRE) after patient care. *Clin Infect Dis*. 2001;32:826–9.
66. Qiao F, Wei L, Feng Y, Ran S, Zheng L, Zhang Y, et al. Handwashing sink contamination and carbapenem-resistant klebsiella infection in the intensive care unit: a prospective multicenter study. *Clin Infect Dis*. 2020;71(Suppl 4):S379–85.
67. Lerner A, Adler A, Abu-Hanna J, Meitus I, Navon-Venezia S, Carmeli Y. Environmental contamination by carbapenem-resistant Enterobacteriaceae. *J Clin Microbiol*. 2013;51:177–81.
68. Ng DHL, Marimuthu K, Lee JJ, Khong WX, Ng OT, Zhang W, et al. Environmental colonization and onward clonal transmission of carbapenem-resistant *Acinetobacter baumannii* (CRAB) in a medical intensive care unit: the case for environmental hygiene. *Antimicrob Resist Infect Control*. 2018;7:51.
69. Hota S, Hirji Z, Stockton K, Lemieux C, Dedier H, Wolfaardt G, et al. Outbreak of multidrug-resistant *Pseudomonas aeruginosa* colonization and infection secondary to imperfect intensive care unit room design. *Infect Control Hosp Epidemiol*. 2009;30:25–33.
70. Kizny Gordon AE, Mathers AJ, Cheong EYL, Gottlieb T, Kotay S, Walker AS, et al. The hospital water environment as a reservoir for carbapenem-resistant organisms causing hospital-acquired infections—a systematic review of the literature. *Clin Infect Dis*. 2017;64:1435–44.
71. Volling C, Ahangari N, Bartoszko JJ, Coleman BL, Garcia-Jeldes F, Jamal AJ, et al. Are sink drainage systems a reservoir for hospital-acquired gamma-proteobacteria colonization and infection? A systematic review. *Open Forum Infect Dis*. 2021;8:ofaa590.
72. Chia PY, Sengupta S, Kukreja A, Ponnampalavanar SSLP, Ng OT, Marimuthu K. The role of hospital environment in transmissions of multidrug-resistant gram-negative organisms. *Antimicrob Resist Infect Control*. 2020;9:29.
73. Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental surfaces in healthcare facilities are a potential source for transmission of *Candida auris* and other *Candida* species. *Infect Control Hosp Epidemiol*. 2017;38:1107–9.
74. Adams E, Quinn M, Tsay S, Poirat E, Chaturvedi S, Southwick K, et al. *Candida auris* in healthcare facilities, New York, USA, 2013–2017. *Emerg Infect Dis*. 2018;24:1816–24.
75. Kramer A, Schwabke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect Dis*. 2006;6:130.
76. Wissmann JE, Kirchhoff L, Bruggemann Y, Todt D, Steinmann J, Steinmann E. Persistence of pathogens on inanimate surfaces: a narrative review. *Microorganisms*. 2021;9(2):343.
77. Traore O, Springthorpe VS, Sattar SA. A quantitative study of the survival of two species of *Candida* on porous and non-porous environmental surfaces and hands. *J Appl Microbiol*. 2002;92:549–55.
78. Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of *Acinetobacter baumannii*. *Am J Infect Control*. 2016;44:e65–71.
79. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast *Candida auris* on a plastic health care surface. *J Clin Microbiol*. 2017;55:2996–3005.
80. Weterings V, Veenemans J, Kleefman A, den Bergh MK, Mulder P, Verhulst C, et al. Evaluation of an in vitro model with a novel statistical approach to measure differences in bacterial survival of extended-spectrum beta-lactamase-producing *Escherichia coli* on an inanimate surface. *Antimicrob Resist Infect Control*. 2019;8:106.
81. Dire O, Ahmad A, Duze S, Patel M. Survival of *Candida auris* on environmental surface materials and low-level resistance to disinfectant. *J Hosp Infect*. 2023;137:17–23.
82. Roghmann MC, Johnson JK, Sorkin JD, Langenberg P, Lydecker A, Sorace B, et al. Transmission of methicillin-resistant *Staphylococcus aureus* (MRSA) to healthcare worker gowns and gloves during care of nursing home residents. *Infect Control Hosp Epidemiol*. 2015;36:1050–7.
83. Wolfensberger A, Clack L, Kuster SP, Passerini S, Mody L, Chopra V, et al. Transfer of pathogens to and from patients, healthcare providers, and medical devices during care activity—a systematic review and meta-analysis. *Infect Control Hosp Epidemiol*. 2018;39:1093–107.
84. Montoya A, Schildhouse R, Goyal A, Mann JD, Snyder A, Chopra V, et al. How often are health care personnel hands colonized with multidrug-resistant organisms? A systematic review and meta-analysis. *Am J Infect Control*. 2019;47:693–703.
85. Ehrenkranz NJ, Alfonso BC. Failure of bland soap handwash to prevent hand transfer of patient bacteria to urethral catheters. *Infect Control Hosp Epidemiol*. 1991;12:654–62.
86. Donskey CJ, Eckstein BC. Images in clinical medicine. The hands give it away. *N Engl J Med*. 2009;360:e3.
87. Landelle C, Verachten M, Legrand P, Girou E, Barbut F, Brun-Buisson C. Contamination of healthcare workers' hands with *Clostridium difficile* spores after caring for patients with *C. difficile* infection. *Infect Control Hosp Epidemiol*. 2014;35:10–5.
88. Longtin Y, Schneider A, Tschopp C, Renzi G, Gayet-Ageron A, Schrenzel J, et al. Contamination of stethoscopes and physicians' hands after a physical examination. *Mayo Clin Proc*. 2014;89:291–9.
89. Tomas ME, Sunkesula VC, Kundrapu S, Wilson BM, Donskey CJ. An intervention to reduce health care personnel hand contamination during care of patients with *Clostridium difficile* infection. *Am J Infect Control*. 2015;43:1366–7.
90. Clack L, Scotoni M, Wolfensberger A, Sax H. "First-person view" of pathogen transmission and hand hygiene-use of a new head-mounted video capture and coding tool. *Antimicrob Resist Infect Control*. 2017;6:108.
91. Kundrapu S, Sunkesula V, Jury LA, Sitzlar BM, Donskey CJ. Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination

- of healthcare workers' hands. *Infect Control Hosp Epidemiol.* 2012;33:1039–42.
92. Jullian-Desayes I, Landelle C, Mallaret MR, Brun-Buisson C, Barbut F. *Clostridium difficile* contamination of health care workers' hands and its potential contribution to the spread of infection: review of the literature. *Am J Infect Control.* 2017;45:51–8.
  93. Hajar Z, Mana TSC, Cadnum JL, Donskey CJ. Dispersal of gram-negative bacilli from contaminated sink drains to cover gowns and hands during hand washing. *Infect Control Hosp Epidemiol.* 2019;40:460–2.
  94. Thom KA, Rock C, Jackson SS, Johnson JK, Srinivasan A, Magder LS, et al. factors leading to transmission risk of *Acinetobacter baumannii*. *Crit Care Med.* 2017;45:e633–9.
  95. Puig-Asensio M, Diekema DJ, Boyken L, Clore GS, Salinas JL, Perencevich EN. Contamination of health-care workers' hands with *Escherichia coli* and *Klebsiella* species after routine patient care: a prospective observational study. *Clin Microbiol Infect.* 2020;26:760–6.
  96. Popovich KJ, Green SJ, Okamoto K, Rhee Y, Hayden MK, Schoeny M, et al. MRSA transmission in intensive care units: genomic analysis of patients, their environments, and healthcare workers. *Clin Infect Dis.* 2021;72:1879–87.
  97. Mody L, McNeil SA, Sun R, Bradley SE, Kauffman CA. Introduction of a waterless alcohol-based hand rub in a long-term-care facility. *Infect Control Hosp Epidemiol.* 2003;24:165–71.
  98. Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, et al. Epidemiologic and molecular characterization of an outbreak of *Candida parapsilosis* bloodstream infections in a community hospital. *J Clin Microbiol.* 2004;42:4468–72.
  99. Delfino D, Scordino F, Pernice I, Lo Passo C, Galbo R, David A, et al. Potential association of specific *Candida parapsilosis* genotypes, bloodstream infections and colonization of health workers' hands. *Clin Microbiol Infect.* 2014;20:O946–51.
  100. Megri Y, Arastehfar A, Boekhout T, Daneshnia F, Hortnagl C, Sartori B, et al. *Candida tropicalis* is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures. *Antimicrob Resist Infect Control.* 2020;9:50.
  101. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, et al. Controlling a possible outbreak of *Candida auris* infection: lessons learnt from multiple interventions. *J Hosp Infect.* 2017;97:363–70.
  102. Lee EH, Choi MH, Lee KH, Kim D, Jeong SH, Song YG, et al. Intrahospital transmission and infection control of *Candida auris* originating from a severely infected COVID-19 patient transferred abroad. *J Hosp Infect.* 2024;143:140–9.
  103. Pittet D, Dharan S, Touveneau S, Sauvan V, Perneger TV. Bacterial contamination of the hands of hospital staff during routine patient care. *Arch Intern Med.* 1999;159:821–6.
  104. Pessoa-Silva CL, Dharan S, Hugonnet S, Touveneau S, Posfay-Barbe K, Pfister R, et al. Dynamics of bacterial hand contamination during routine neonatal care. *Infect Control Hosp Epidemiol.* 2004;25:192–7.
  105. Morgan DJ, Liang SY, Smith CL, Johnson JK, Harris AD, Furuno JP, et al. Frequent multidrug-resistant *Acinetobacter baumannii* contamination of gloves, gowns, and hands of healthcare workers. *Infect Control Hosp Epidemiol.* 2010;31:716–21.
  106. Okamoto K, Rhee Y, Schoeny M, Lolans K, Cheng J, Reddy S, et al. Impact of doffing errors on healthcare worker self-contamination when caring for patients on contact precautions. *Infect Control Hosp Epidemiol.* 2019;40:559–65.
  107. Snyder GM, Thom KA, Furuno JP, Perencevich EN, Roghmann MC, Strauss SM, et al. Detection of methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci on the gowns and gloves of healthcare workers. *Infect Control Hosp Epidemiol.* 2008;29:583–9.
  108. Stiefel U, Cadnum JL, Eckstein BC, Guerrero DM, Tima MA, Donskey CJ. Contamination of hands with methicillin-resistant *Staphylococcus aureus* after contact with environmental surfaces and after contact with the skin of colonized patients. *Infect Control Hosp Epidemiol.* 2011;32:185–7.
  109. Tomas ME, Kundrapu S, Thota P, Sunkesula VC, Cadnum JL, Mana TS, et al. Contamination of health care personnel during removal of personal protective equipment. *JAMA Intern Med.* 2015;175:1904–10.
  110. Lacey RW, Alder VG, Gillespie WA. The survival of *Staphylococcus aureus* on human skin. An investigation using mixed cultures. *Br J Exp Pathol.* 1970;51:305–13.
  111. Baede VO, Voet MM, van der Reijden TJK, van Wengen A, Horst-Kreft DE, Lemmens-den Toom NA, et al. The survival of epidemic and sporadic MRSA on human skin mimics is determined by both host and bacterial factors. *Epidemiol Infect.* 2022;150:e203.
  112. Casewell MW, Desai N. Survival of multiply-resistant *Klebsiella aerogenes* and other gram-negative bacilli on finger-tips. *J Hosp Infect.* 1983;4:350–60.
  113. Musa EK, Desai N, Casewell MW. The survival of *Acinetobacter calcoaceticus* inoculated on fingertips and on formica. *J Hosp Infect.* 1990;15:219–27.
  114. Fryklund B, Tullus K, Burman LG. Survival on skin and surfaces of epidemic and non-epidemic strains of enterobacteria from neonatal special care units. *J Hosp Infect.* 1995;29:201–8.
  115. Doring G, Jansen S, Noll H, Grupp H, Frank F, Botzenhart K, et al. Distribution and transmission of *Pseudomonas aeruginosa* and *Burkholderia cepacia* in a hospital ward. *Pediatr Pulmonol.* 1996;21:90–100.
  116. Edmonds SL, Zapka C, Kasper D, Gerber R, McCormack R, Macinga D, et al. Effectiveness of hand hygiene for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol.* 2013;34:302–5.
  117. Boyce JM, Potter-Bynoe G, Opal SM, Dziobek L, Medeiros AA. A common-source outbreak of *Staphylococcus epidermidis* infections among patients undergoing cardiac surgery. *J Infect Dis.* 1990;161:493–9.
  118. Weber S, Herwaldt LA, McNutt LA, Rhomburg P, Vaudaux P, Pfaller MA, et al. An outbreak of *Staphylococcus aureus* in a pediatric cardiothoracic surgery unit. *Infect Control Hosp Epidemiol.* 2002;23:77–81.
  119. Parry MF, Hutchinson JH, Brown NA, Wu CH, Estreller L. Gram-negative sepsis in neonates: a nursery outbreak due to hand carriage of *Citrobacter diversus*. *Pediatrics.* 1980;65:1105–9.
  120. Mermel LA, McKay M, Dempsey J, Parenteau S. *Pseudomonas* surgical-site infections linked to a healthcare worker with onychomycosis. *Infect Control Hosp Epidemiol.* 2003;24:749–52.
  121. McNeil SA, Nordstrom-Lerner L, Malani PN, Zervos M, Kauffman CA. Outbreak of sternal surgical site infections due to *Pseudomonas aeruginosa* traced to a scrub nurse with onychomycosis. *Clin Infect Dis.* 2001;33:317–23.
  122. Zawacki A, O'Rourke E, Potter-Bynoe G, Macone A, Harbarth S, Goldmann D. An outbreak of *Pseudomonas aeruginosa* pneumonia and bloodstream infection associated with intermittent otitis externa in a healthcare worker. *Infect Control Hosp Epidemiol.* 2004;25:1083–9.
  123. Moolenaar RL, Crutcher M, San Joaquin VH, Sewell LV, Hutwagner LC, Carlson LA, et al. A prolonged outbreak of *Pseudomonas aeruginosa* in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? *Infect Control Hosp Epidemiol.* 2000;21:80–5.
  124. de Vries JJ, Baas WH, van der Ploeg K, Heesink A, Degener JE, Arends JP. Outbreak of *Serratia marcescens* colonization and infection traced to a healthcare worker with long-term carriage on the hands. *Infect Control Hosp Epidemiol.* 2006;27:1153–8.
  125. Gupta A, Della-Latta P, Todd B, San Gabriel P, Haas J, Wu F, et al. Outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit linked to artificial nails. *Infect Control Hosp Epidemiol.* 2004;25:210–5.
  126. Isenberg HD, Tucci V, Cintron F, Singer C, Weinstein GS, Tyras DH. Single-source outbreak of *Candida tropicalis* complicating coronary bypass surgery. *J Clin Microbiol.* 1989;27:2426–8.
  127. Ullrich C, Luescher AM, Koch J, Grass RN, Sax H. Silica nanoparticles with encapsulated DNA (SPED) to trace the spread of pathogens in health-care. *Antimicrob Resist Infect Control.* 2022;11:4.
  128. Mitchell BG, McDonagh J, Dancer SJ, Ford S, Sim J, Khadar BTSa, et al. Risk of organism acquisition from prior room occupants: an updated systematic review. *Infect Dis Health.* 2023;28:290–7.
  129. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect.* 2014;20(Suppl 1):1–55.
  130. World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in Health Care Facilities. Geneva. 2017. [https://www.ncbi.nlm.nih.gov/books/NBK493061/pdf/Bookshelf\\_NBK493061.pdf](https://www.ncbi.nlm.nih.gov/books/NBK493061/pdf/Bookshelf_NBK493061.pdf).

131. Mills JP, Marchaim D. Multidrug-resistant gram-negative bacteria: infection prevention and control update. *Infect Dis Clin North Am*. 2021;35:969–94.
132. Popovich KJ, Aureden K, Ham DC, Harris AD, Hessels AJ, Huang SS, et al. SHEA/IDSA/APIC practice recommendation: strategies to prevent methicillin-resistant *Staphylococcus aureus* transmission and infection in acute-care hospitals: 2022 Update. *Infect Control Hosp Epidemiol*. 2023;44:1039–67.
133. Tinelli M, Tiseo G, Falcone M, Elderly ESGflit. Prevention of the spread of multidrug-resistant organisms in nursing homes. *Aging Clin Exp Res*. 2021; 33:679–87.
134. Kocielek LK, Gerding DN, Carrico R, Carling P, Donskey CJ, Dumyati G, et al. Strategies to prevent *Clostridioides difficile* infections in acute-care hospitals: 2022 update. *Infect Control Hosp Epidemiol*. 2023;44:527–49.
135. Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, et al. Control of carbapenem-resistant enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. *Clin Infect Dis*. 2019;68:873–84.
136. Derde LPG, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJJ, Gniadkowski M, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. *Lancet Infect Dis*. 2014;14:31–9.
137. Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant enterobacteriaceae: a strategic roadmap for infection control. *Infect Control Hosp Epidemiol*. 2017;38:580–94.
138. Glowicz JB, Landon E, Sickbert-Bennett EE, Aiello AE, deKay K, Hoffmann KK, et al. SHEA/IDSA/APIC practice recommendation: strategies to prevent healthcare-associated infections through hand hygiene: 2022 update. *Infect Control Hosp Epidemiol*. 2023;44:355–76.
139. Moro ML, Morsillo F, Nascetti S, Parenti M, Allegranzi B, Pompa MG, et al. Determinants of success and sustainability of the WHO multimodal hand hygiene promotion campaign, Italy, 2007–2008 and 2014. *Euro Surveill*. 2017;22:30546.
140. Saitoh A, Sato K, Magara Y, Osaki K, Narita K, Shioiri K, et al. Improving hand hygiene adherence in healthcare workers before patient contact: a multimodal intervention in four tertiary care hospitals in Japan. *J Hosp Med*. 2020;15(5):262–7.
141. World Health Organization. Evidence of hand hygiene to reduce transmission and infections by multi-drug resistant organisms in health-care settings. WHO. 2014. [https://cdn.who.int/media/docs/default-source/integrated-health-services-\(ihs\)/infection-prevention-and-control/mdro-literature-review.pdf?sfvrsn=88dd45c7\\_2](https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/infection-prevention-and-control/mdro-literature-review.pdf?sfvrsn=88dd45c7_2).
142. Pittet D, Hugonnet S, Harbarth S, Mourougat P, Sauvan V, Touveneau S. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *Lancet*. 2000;356:1307–12.
143. Grayson ML, Jarvie LJ, Martin R, Johnson PD, Jodoin ME, McMullan C, et al. Significant reductions in methicillin-resistant *Staphylococcus aureus* bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. *Med J Aust*. 2008;188:633–40.
144. De la Rosa-Zamboni D, Ochoa SA, Laris-Gonzalez A, Cruz-Cordova A, Escalona-Venegas G, Perez-Avendano G, et al. Everybody hands-on to avoid ESKAPE: effect of sustained hand hygiene compliance on healthcare-associated infections and multidrug resistance in a paediatric hospital. *J Med Microbiol*. 2018;67:1761–71.
145. Chen YC, Sheng WH, Wang JT, Chang SC, Lin HC, Tien KL, et al. Effectiveness and limitations of hand hygiene promotion on decreasing healthcare-associated infections. *PLoS ONE*. 2011;6:e27163.
146. Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE, Weber DJ. Susceptibility of *Candida auris* and *Candida albicans* to 21 germicides used in healthcare facilities. *Infect Control Hosp Epidemiol*. 2019;40:380–2.
147. Centers for Disease Control and Prevention. Infection Prevention and Control for *Candida auris*. 2023. <https://www.cdc.gov/candida-auris/hcp/infection-control/index.html>.
148. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. *MMWR Recomm Rep*. 2011;60(RR-3):1–18.
149. Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild M, Barbut F, Eckert C, et al. Guidance document for prevention of *Clostridium difficile* infection in acute healthcare settings. *Clin Microbiol Infect*. 2018;24:1051–4.
150. Johnston CP, Qiu H, Ticehurst JR, Dickson C, Rosenbaum P, Lawson P, et al. Outbreak management and implications of a nosocomial norovirus outbreak. *Clin Infect Dis*. 2007;45:534–40.
151. Khanna N, Goldenberger D, Graber P, Battegay M, Widmer AF. Gastroenteritis outbreak with norovirus in a Swiss university hospital with a newly identified virus strain. *J Hosp Infect*. 2003;55:131–6.
152. Cheng VC, Tai JW, Ho YY, Chan JF. Successful control of norovirus outbreak in an infirmary with the use of alcohol-based hand rub. *J Hosp Infect*. 2009;72:370–1.
153. Gould DJ, Moralejo D, Drey N, Chudleigh JH, Taljaard M. Interventions to improve hand hygiene compliance in patient care. *Cochrane Database Syst Rev*. 2017;9:CD005186.
154. Sickbert-Bennett EE, DiBiase LM, Willis TM, Wolak ES, Weber DJ, Rutala WA. Reduction of healthcare-associated infections by exceeding high compliance with hand hygiene practices. *Emerg Infect Dis*. 2016;22:1628–30.
155. Talbot TR, Johnson JG, Fergus C, Domenico JH, Schaffner W, Daniels TL, et al. Sustained improvement in hand hygiene adherence: utilizing shared accountability and financial incentives. *Infect Control Hosp Epidemiol*. 2013;34:1129–36.
156. Allegranzi B, Harbarth S, Pittet D. Effect of hand hygiene on infection rates. In: Pittet D, Boyce JM, Allegranzi B, editors. *Hand hygiene: a handbook for medical professionals*. Hoboken: Wiley-Blackwell; 2017. p. 299–316.
157. Boyce JM, Ligi C, Kohan C, Dumigan D, Havill NL. Lack of association between the increased incidence of *Clostridium difficile*-associated disease and the increasing use of alcohol-based hand rubs. *Infect Control Hosp Epidemiol*. 2006;27:479–83.
158. Kaier K, Hagist C, Frank U, Conrad A, Meyer E. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant *Staphylococcus aureus* infection and *Clostridium difficile* infection. *Infect Control Hosp Epidemiol*. 2009;30:346–53.
159. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and *Clostridium difficile*. *J Antimicrob Chemother*. 2008;62:601–7.
160. Gordin FM, Schultz ME, Huber RA, Gill JA. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. *Infect Control Hosp Epidemiol*. 2005;26:650–3.
161. Kramer A, Rudolph P, Kampf G, Pittet D. Limited efficacy of alcohol-based hand gels. *Lancet*. 2002;359:1489–90.
162. Dharan S, Hugonnet S, Sax H, Pittet D. Comparison of waterless hand antiseptics agents at short application times: raising the flag of concern. *Infect Control Hosp Epidemiol*. 2003;24:160–4.
163. Rupp ME, Fitzgerald T, Puumala S, Anderson JR, Craig R, Iwen PC, et al. Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units. *Infect Control Hosp Epidemiol*. 2008;29:8–15.
164. Kampf G, Marschall S, Eggerstedt S, Ostermeyer C. Efficacy of ethanol-based hand foams using clinically relevant amounts: a cross-over controlled study among healthy volunteers. *BMC Infect Dis*. 2010;10:78.
165. Kampf G, Ruselack S, Eggerstedt S, Nowak N, Bashir M. Less and less-influence of volume on hand coverage and bactericidal efficacy in hand disinfection. *BMC Infect Dis*. 2013;13:472.
166. Edmonds SL, Macinga DR, Mays-Suko P, Duley C, Rutter J, Jarvis WR, et al. Comparative efficacy of commercially available alcohol-based hand rubs and World Health Organization-recommended hand rubs: formulation matters. *Am J Infect Control*. 2012;40:521–5.
167. Macinga DR, Shumaker DJ, Werner HP, Edmonds SL, Leslie RA, Parker AE, et al. The relative influences of product volume, delivery format and alcohol concentration on dry-time and efficacy of alcohol-based hand rubs. *BMC Infect Dis*. 2014;14:511.
168. Edmonds-Wilson S, Campbell E, Fox K, Macinga D. Comparison of 3 in vivo methods for assessment of alcohol-based hand rubs. *Am J Infect Control*. 2015;43:506–9.
169. Wilkinson MAC, Ormandy K, Bradley CR, Hines J. Comparison of the efficacy and drying times of liquid, gel and foam formats of alcohol-based hand rubs. *J Hosp Infect*. 2018;98:359–64.



170. Boyce JM, Pittet D. Rinse, gel, and foam - is there any evidence for a difference in their effectiveness in preventing infections? *Antimicrob Resist Infect Control*. 2024;13:49.
171. Karmarkar EN, O'Donnell K, Prestel C, Forsberg K, Gade L, Jain S, et al. Rapid assessment and containment of *Candida auris* transmission in postacute care settings-Orange County, California, 2019. *Ann Intern Med*. 2021;174:1554–62.
172. Rankin DA, Walters MS, Caicedo L, Gable P, Moulton-Meissner HA, Chan A, et al. Concurrent transmission of multiple carbapenemases in a long-term acute-care hospital. *Infect Control Hosp Epidemiol*. 2024;45:292–301.
173. Cho OH, Bak MH, Baek EH, Park KH, Kim S, Bae IG. Successful control of carbapenem-resistant *Acinetobacter baumannii* in a Korean university hospital: a 6-year perspective. *Am J Infect Control*. 2014;42:976–9.
174. Papanikolopoulou A, Maltezos HC, Stoupis A, Pangalis A, Kouroumpetsis C, Chronopoulou G, et al. Ventilator-associated pneumonia, multidrug-resistant bacteremia and infection control interventions in an intensive care unit: analysis of six-year time-series data. *Antibiotics (Basel)*. 2022;11:1128.
175. Boyce JM. Current issues in hand hygiene. *Am J Infect Control*. 2023;51(11S):A35–43.
176. Tschudin-Sutter S, Sepulcri D, Dangel M, Ulrich A, Frei R, Widmer AF. Simplifying the WHO protocol: three steps versus six steps for performance of hand hygiene - a cluster-randomized trial. *Clin Infect Dis*. 2019;69:614–20.
177. Lotfinejad N, Peters A, Tartari E, Fankhauser-Rodriguez C, Pires D, Pittet D. Hand hygiene in health care: 20 years of ongoing advances and perspectives. *Lancet Infect Dis*. 2021;21:e209–21.
178. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in healthcare-associated infections. *Curr Opin Infect Dis*. 2013;26:338–44.
179. Dancer SJ. Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination. *Clin Microbiol Rev*. 2014;27:665–90.
180. Han JH, Sullivan N, Leas BF, Pegues DA, Kaczmarek JL, Umscheid CA. Cleaning hospital room surfaces to prevent health care-associated infections, a technical brief. *Ann Intern Med*. 2015;163:598–607.
181. Carling PC. Optimizing health care environmental hygiene. *Infect Dis Clin North Am*. 2016;30:639–60.
182. Rutala WA, Weber DJ. Best practices for disinfection of noncritical environmental surfaces and equipment in health care facilities: a bundle approach. *Am J Infect Control*. 2019;47S:A96–105.
183. Donskey CJ. Does improving surface cleaning and disinfection reduce health care-associated infections? *Am J Infect Control*. 2013;41(5 Suppl):S12–9.
184. Siani H, Maillard JY. Best practice in healthcare environment decontamination. *Eur J Clin Microbiol Infect Dis*. 2015;34:1–11.
185. Peters A, Schmid MN, Parneix P, Lebowitz D, de Kraker M, Sauser J, et al. Impact of environmental hygiene interventions on healthcare-associated infections and patient colonization: a systematic review. *Antimicrob Resist Infect Control*. 2022;11:38.
186. Thomas RE, Thomas BC, Conly J, Lorenzetti D. Cleaning and disinfecting surfaces in hospitals and long-term care facilities for reducing hospital- and facility-acquired bacterial and viral infections: a systematic review. *J Hosp Infect*. 2022;122:9–26.
187. Han Z, Pappas E, Simmons A, Fox J, Donskey CJ, Deshpande A. Environmental cleaning and disinfection of hospital rooms: a nationwide survey. *Am J Infect Control*. 2021;49:34–9.
188. van Dijk MD, Voor In't Holt AF, Alp E, Hell M, Petrosillo N, Presterl E, et al. Infection prevention and control policies in hospitals and prevalence of highly resistant microorganisms: an international comparative study. *Antimicrob Resist Infect Control*. 2022;11:152.
189. Havill NL. Best practices in disinfection of noncritical surfaces in the health care setting: creating a bundle for success. *Am J Infect Control*. 2013;41(5 Suppl):S26–30.
190. Mitchell BG, Hall L, White N, Barnett AG, Halton K, Paterson DL, et al. An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. *Lancet Infect Dis*. 2019;19:410–8.
191. Barker AK, Scaria E, Safdar N, Alagoz O. Evaluation of the cost-effectiveness of infection control strategies to reduce hospital-onset *Clostridioides difficile* infection. *JAMA Netw Open*. 2020;3:e2012522.
192. (KRINKO) Commission for Hospital Hygiene and Infection Prevention. Hygiene requirements for cleaning and disinfection of surfaces: recommendation of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute. *GMS Hyg Infect Control*. 2024;19:1–48.
193. Donskey CJ, Sunkesula VCK, Stone ND, Gould CV, McDonald LC, Samore M, et al. Transmission of *Clostridium difficile* from asymptotically colonized or infected long-term care facility residents. *Infect Control Hosp Epidemiol*. 2018;39:909–16.
194. Alon D, Mudrik H, Chowdhary M, Shitrit P. Control of a hospital-wide outbreak of carbapenem-resistant *Acinetobacter baumannii* (CRAB) using the Israeli national carbapenem-resistant Enterobacteriaceae (CRE) guidelines as a model. *Infect Control Hosp Epidemiol*. 2020;41:926–30.
195. Mody L, Gontjes KJ, Cassone M, Gibson KE, Lansing BJ, Mantey J, et al. Effectiveness of a multicomponent intervention to reduce multidrug-resistant organisms in nursing homes: a cluster randomized clinical trial. *JAMA Netw Open*. 2021;4:e2116555.
196. Kenters N, Kiernan M, Chowdhary A, Denning DW, Peman J, Saris K, et al. Control of *Candida auris* in healthcare institutions: outcome of an international society for antimicrobial chemotherapy expert meeting. *Int J Antimicrob Agents*. 2019;54:400–6.
197. Cheng KL, Boost MV, Chung JW. Study on the effectiveness of disinfection with wipes against methicillin-resistant *Staphylococcus aureus* and implications for hospital hygiene. *Am J Infect Control*. 2011;39:577–80.
198. Gavalda L, Pequeno S, Soriano A, Dominguez MA. Environmental contamination by multidrug-resistant microorganisms after daily cleaning. *Am J Infect Control*. 2015;43:776–8.
199. Cheon S, Kim MJ, Yun SJ, Moon JY, Kim YS. Controlling endemic multidrug-resistant *Acinetobacter baumannii* in intensive care units using antimicrobial stewardship and infection control. *Korean J Intern Med*. 2016;31:367–74.
200. Weber DJ, Rutala WA, Sickbert-Bennett E. Outbreaks associated with contaminated antiseptics and disinfectants. *Antimicrob Agents Chemother*. 2007;51:4217–24.
201. Kampf G, Degenhardt S, Lackner S, Jesse K, von Baum H, Ostermeyer C. Poorly processed reusable surface disinfection tissue dispensers may be a source of infection. *BMC Infect Dis*. 2014;14:37.
202. Boyce JM, Havill NL. In-use contamination of a hospital-grade disinfectant. *Am J Infect Control*. 2022;50:1296–301.
203. Dumigan DG, Boyce JM, Havill NL, Golebiewski M, Balogun O, Rizvani R. Who is really caring for your environment of care? Developing standardized cleaning procedures and effective monitoring techniques. *Am J Infect Control*. 2010;38:387–92.
204. Magiorakos AP, Burns K, Rodriguez Bano J, Borg M, Daikos G, Dumpis U, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. *Antimicrob Resist Infect Control*. 2017;6:113.
205. Dancer SJ, King MF. Systematic review on use, cost and clinical efficacy of automated decontamination devices. *Antimicrob Resist Infect Control*. 2021;10:34.
206. Rutala WA, Donskey CJ, Weber DJ. Disinfection and sterilization: new technologies. *Am J Infect Control*. 2023;51(11S):A13–21.
207. Tyan K, Cohen PA. Investing in our first line of defense: environmental services workers. *Ann Intern Med*. 2020;173:306–7.
208. Goedken CC, McKinley L, Balkenende E, Hockett Sherlock S, Knobloch MJ, Perencevich EN, et al. "Our job is to break that chain of infection": challenges environmental management services (EMS) staff face in accomplishing their critical role in infection prevention. *Antimicrob Steward Healthc Epidemiol*. 2022;2:e129.
209. Rutala WA, Gergen MF, Weber DJ. Efficacy of different cleaning and disinfection methods against *Clostridium difficile* spores: importance of physical removal versus sporicidal inactivation. *Infect Control Hosp Epidemiol*. 2012;33:1255–8.
210. Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of *Clostridium difficile* infection. *J Hosp Infect*. 2003;54:109–14.

211. Alfa MJ, Lo E, Olson N, MacRae M, Buelow-Smith L. Use of a daily disinfectant cleaner instead of a daily cleaner reduced hospital-acquired infection rates. *Am J Infect Control*. 2015;43:141–6.
212. Ramm L, Siani H, Wesgate R, Maillard JY. Pathogen transfer and high variability in pathogen removal by detergent wipes. *Am J Infect Control*. 2015;43:724–8.
213. Donskey CJ. Update on potential interventions to reduce the risk for transmission of health care-associated pathogens from floors and sinks. *Am J Infect Control*. 2023;51(11S):A120–5.
214. Dharan S, Mourouga P, Copin P, Bessmer G, Tschanz B, Pittet D. Routine disinfection of patients' environmental surfaces. Myth or reality? *J Hosp Infect*. 1999;42:113–7.
215. Wong T, Woznow T, Petrie M, Murzello E, Muniak A, Kadora A, et al. Postdischarge decontamination of MRSA, VRE, and *Clostridium difficile* isolation rooms using 2 commercially available automated ultraviolet-C-emitting devices. *Am J Infect Control*. 2016;44:416–20.
216. Mustapha A, Alhmidhi H, Cadnum JL, Jencson AL, Donskey CJ. Efficacy of manual cleaning and an ultraviolet C room decontamination device in reducing health care-associated pathogens on hospital floors. *Am J Infect Control*. 2018;46:584–6.
217. Rutala WA, Weber DJ. Disinfection and sterilization in health care facilities: an overview and current issues. *Infect Dis Clin North Am*. 2021;35:575–607.
218. Kenters N, Huijskens EGW, de Wit SCJ, Sanders IGJM, van Rosmalen J, Kuijper EJ, et al. Effectiveness of various cleaning and disinfectant products on *Clostridium difficile* spores of PCR ribotypes 010, 014 and 027. *Antimicrob Resist Infect Control*. 2017;6:54.
219. Reichel M, Schlicht A, Ostermeyer C, Kampf G. Efficacy of surface disinfectant cleaners against emerging highly resistant gram-negative bacteria. *BMC Infect Dis*. 2014;14:292.
220. Rutala WA, Weber D. J., and the Healthcare Infection Practices Advisory Committee (HICPAC). Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008—Update 2019. [https://www.cdc.gov/infection-control/hcp/disinfection-andsterilization/?CDC\\_AAref\\_Val=https://www.cdc.gov/infectioncontrol/guidelines/disinfection/](https://www.cdc.gov/infection-control/hcp/disinfection-andsterilization/?CDC_AAref_Val=https://www.cdc.gov/infectioncontrol/guidelines/disinfection/).
221. Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL, Larkin EL, et al. Effectiveness of disinfectants against *Candida auris* and other *Candida* Species. *Infect Control Hosp Epidemiol*. 2017;38:1240–3.
222. United States Environmental Protection Agency. EPA's registered antimicrobial products effective against *Candida auris* [List P]. 2024. <https://www.epa.gov/pesticide-registration/epas-registered-antimicrobial-products-effective-against-candida-auris-list#against>.
223. Kean R, Sherry L, Townsend E, McKlound E, Short B, Akinbobola A, et al. Surface disinfection challenges for *Candida auris*: an in-vitro study. *J Hosp Infect*. 2018;98:433–6.
224. Song X, Vossebein L, Zille A. Efficacy of disinfectant-impregnated wipes used for surface disinfection in hospitals: a review. *Antimicrob Resist Infect Control*. 2019;8:139.
225. Casini B, Righi A, De FN, Totaro M, Giorgi S, Zezza L, et al. Improving cleaning and disinfection of high-touch surfaces in intensive care during carbapenem-resistant *Acinetobacter baumannii* endemo-epidemic situations. *Int J Environ Res Public Health*. 2018;15:2305.
226. Kenters N, Huijskens EGW, de Wit SCJ, van Rosmalen J, Voss A. Effectiveness of cleaning-disinfection wipes and sprays against multidrug-resistant outbreak strains. *Am J Infect Control*. 2017;45:e69–73.
227. Siani H, Wesgate R, Maillard JY. Impact of antimicrobial wipes compared with hypochlorite solution on environmental surface contamination in a health care setting: a double-crossover study. *Am J Infect Control*. 2018;46:1180–7.
228. Boyce JM, Guercia KA, Sullivan L, Havill NL, Fekieta R, Kozakiewicz J, et al. Prospective cluster controlled crossover trial to compare the impact of an improved hydrogen peroxide disinfectant and a quaternary ammonium-based disinfectant on surface contamination and health care outcomes. *Am J Infect Control*. 2017;45:1006–10.
229. Hayden MK, Bonten MJ, Blom DW, Lyle EA, van de Vijver DA, Weinstein RA. Reduction in acquisition of vancomycin-resistant *Enterococcus* after enforcement of routine environmental cleaning measures. *Clin Infect Dis*. 2006;42:1552–60.
230. Parry MF, Sestovic M, Renz C, Pangan A, Grant B, Shah AK. Environmental cleaning and disinfection: sustaining changed practice and improving quality in the community hospital. *Antimicrob Steward Healthc Epidemiol*. 2022;2:e113.
231. Mitchell BG, Digney W, Locket P, Dancer SJ. Controlling methicillin-resistant *Staphylococcus aureus* (MRSA) in a hospital and the role of hydrogen peroxide decontamination: an interrupted time series analysis. *BMJ Open*. 2014;4:e004522.
232. Datta R, Platt R, Yokoe DS, Huang SS. Environmental cleaning intervention and risk of acquiring multidrug-resistant organisms from prior room occupants. *Arch Intern Med*. 2011;171:491–4.
233. Centers for Disease Control and Prevention. Options for evaluating environmental cleaning. 2010. <https://www.cdc.gov/infection-control/media/pdfs/Toolkits-Environmental-Cleaning-Evaluation-2010-P.pdf>.
234. Deshpande A, Donskey CJ. Practical approaches for assessment of daily and post-discharge room disinfection in healthcare facilities. *Curr Infect Dis Rep*. 2017;19:32.
235. Sitzlar B, Deshpande A, Fertelli D, Kundrapu S, Sethi AK, Donskey CJ. An environmental disinfection odyssey: evaluation of sequential interventions to improve disinfection of *Clostridium difficile* isolation rooms. *Infect Control Hosp Epidemiol*. 2013;34:459–65.
236. Boyce JM, Havill NL, Lipka A, Havill H, Rizvani R. Variations in hospital daily cleaning practices. *Infect Control Hosp Epidemiol*. 2010;31:99–101.
237. Rupp ME, Adler A, Schellen M, Cassling K, Fitzgerald T, Sholtz L, et al. The time spent cleaning a hospital room does not correlate with the thoroughness of cleaning. *Infect Control Hosp Epidemiol*. 2013;34:100–2.
238. Lerner AO, Abu-Hanna J, Carmeli Y, Schechner V. Environmental contamination by carbapenem-resistant *Acinetobacter baumannii*: the effects of room type and cleaning methods. *Infect Control Hosp Epidemiol*. 2020;41:166–71.
239. Rock C, Small BA, Hsu YJ, Gurses AP, Xie A, Scheeler V, et al. Evaluating accuracy of sampling strategies for fluorescent gel monitoring of patient room cleaning. *Infect Control Hosp Epidemiol*. 2019;40:794–7.
240. Enfield KB, Huq NN, Gosseling MF, Low DJ, Hazen KC, Toney DM, et al. Control of simultaneous outbreaks of carbapenemase-producing enterobacteriaceae and extensively drug-resistant *Acinetobacter baumannii* infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012 carbapenemase-resistant Enterobacteriaceae Toolkit. *Infect Control Hosp Epidemiol*. 2014;35:810–7.
241. Deshpande A, Sitzlar B, Fertelli D, Kundrapu S, Sunkesula VC, Ray AJ, et al. Utility of an adenosine triphosphate bioluminescence assay to evaluate disinfection of *Clostridium difficile* isolation rooms. *Infect Control Hosp Epidemiol*. 2013;34:865–7.
242. Ziegler MJ, Babcock HH, Welbel SF, Warren DK, Trick WE, Tolomeo P, et al. Stopping hospital infections with environmental services (SHINE): a cluster-randomized trial of intensive monitoring methods for terminal room cleaning on rates of multidrug-resistant organisms in the intensive care unit. *Clin Infect Dis*. 2022;75:1217–23.
243. Whiteley GS, Derry C, Glasbey T, Fahey P. The perennial problem of variability in adenosine triphosphate (ATP) tests for hygiene monitoring within healthcare settings. *Infect Control Hosp Epidemiol*. 2015;36:658–63.
244. Rawlinson S, Ciric L, Cloutman-Green E. How to carry out microbiological sampling of healthcare environment surfaces? A review of current evidence. *J Hosp Infect*. 2019;103:363–74.
245. Knelson LP, Ramadanovic GK, Chen LF, Moehring RW, Lewis SS, Rutala WA, et al. Self-monitoring by environmental services may not accurately measure thoroughness of hospital room cleaning. *Infect Control Hosp Epidemiol*. 2017;38:1371–3.
246. Donskey CJ. Decontamination devices in health care facilities: practical issues and emerging applications. *Am J Infect Control*. 2019;47S:A23–8.
247. van der Starre CM, Cremers-Pijpers SAJ, van Rossum C, Bowles EC, Tostmann A. The in situ efficacy of whole room disinfection devices: a literature review with practical recommendations for implementation. *Antimicrob Resist Infect Control*. 2022;11:149.
248. Rock C, Hsu YJ, Curless MS, Carroll KC, Ross Howard T, Carson KA, et al. Ultraviolet-C light evaluation as adjunct disinfection to remove multidrug-resistant organisms. *Clin Infect Dis*. 2022;75:35–40.
249. Otter JA, Yezli S, Schouten MA, van Zanten AR, Houmes-Zielman G, Nohlmans-Paulssen MK. Hydrogen peroxide vapor decontamination of an intensive care unit to remove environmental reservoirs of

- multidrug-resistant gram-negative rods during an outbreak. *Am J Infect Control*. 2010;38:754–6.
250. Otter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. *Clin Microbiol Infect*. 2017;23:188–96.
  251. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al. Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *SciTransl Med*. 2012;4:148ra116.
  252. Passaretti CL, Otter JA, Reich NG, Myers J, Shepard J, Ross T, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. *Clin Infect Dis*. 2013;56:27–35.
  253. Marra AR, Schweizer ML, Edmond MB. No-touch disinfection methods to decrease multidrug-resistant organism infections: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol*. 2018;39:20–31.
  254. Anderson DJ, Moehring RW, Weber DJ, Lewis SS, Chen LF, Schwab JC, et al. Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and *Clostridium difficile*: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection). *Lancet Infect Dis*. 2018;18:845–53.
  255. European Centre for Disease Prevention and Control. *Candida auris* in healthcare settings - Europe. 2016. <https://www.ecdc.europa.eu/sites/default/files/documents/RRACandida-auris-European-Union-countries.pdf>.
  256. Ciobotaro P, Oved M, Nadir E, Bardenstein R, Zimhony O. An effective intervention to limit the spread of an epidemic carbapenem-resistant *Klebsiella pneumoniae* strain in an acute care setting: from theory to practice. *Am J Infect Control*. 2011;39:671–7.
  257. Suarez C, Pena C, Arch O, Dominguez MA, Tubau F, Juan C, et al. A large sustained endemic outbreak of multiresistant *Pseudomonas aeruginosa*: a new epidemiological scenario for nosocomial acquisition. *BMC Infect Dis*. 2011;11:272.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.